日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules

对FDA批准的肿瘤小分子药物的不良事件和剂量强度进行分析

Collins, Keagan P; Yin, Donghua; Pithavala, Yazdi K; Mittapalli, Rajendar K

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

评估洛拉替尼对晚期非小细胞肺癌患者CYP2B6、CYP2C9、UGT和P-糖蛋白底物的影响

Chen, Joseph; Bearz, Alessandra; Kim, Dong-Wan; Mamdani, Hirva; Bauman, Jessica; Chiari, Rita; Ou, Sai-Hong Ignatius; Solomon, Benjamin J; Soo, Ross A; Felip, Enriqueta; Shaw, Alice T; Thurm, Holger; Clancy, Jill S; Lee, Kimberly; O'Gorman, Melissa; Tanski, Cherie; Pithavala, Yazdi K

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

在健康受试者中评估间变性淋巴瘤激酶/c-ROS癌基因1激酶抑制剂劳拉替尼的绝对口服生物利用度

Hibma, Jennifer E; O'Gorman, Melissa; Nepal, Sunil; Pawlak, Sylvester; Ginman, Katherine; Pithavala, Yazdi K

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

洛拉替尼的脑渗透性:既往接受过治疗的ALK阳性非小细胞肺癌患者使用洛拉替尼治疗后中枢神经系统和非中枢神经系统进展的累积发生率

Bauer, Todd M; Shaw, Alice T; Johnson, Melissa L; Navarro, Alejandro; Gainor, Justin F; Thurm, Holger; Pithavala, Yazdi K; Abbattista, Antonello; Peltz, Gerson; Felip, Enriqueta

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

肾功能损害对阿昔替尼药代动力学和安全性的影响

Chen, Ying; Rini, Brian I; Motzer, Robert J; Dutcher, Janice P; Rixe, Olivier; Wilding, George; Stadler, Walter M; Tarazi, Jamal; Garrett, May; Pithavala, Yazdi K

Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

基于模型的荟萃分析,对接受抗血管生成治疗的晚期肝细胞癌患者研究进行临床试验模拟

Zierhut, M L; Chen, Y; Pithavala, Y K; Nickens, D J; Valota, O; Amantea, M A

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses

阿昔替尼治疗不同组织学亚型晚期甲状腺癌患者的II期试验:长期疗效及药代动力学/药效学分析

Cohen, E E W; Tortorici, M; Kim, S; Ingrosso, A; Pithavala, Y K; Bycott, P

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

阿昔替尼联合或不联合剂量滴定治疗一线转移性肾细胞癌:一项随机双盲 II 期试验

Rini, Brian I; Melichar, Bohuslav; Ueda, Takeshi; Grünwald, Viktor; Fishman, Mayer N; Arranz, José A; Bair, Angel H; Pithavala, Yazdi K; Andrews, Glen I; Pavlov, Dmitri; Kim, Sinil; Jonasch, Eric

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis

阿昔替尼治疗转移性肾细胞癌:药代动力学和药效学分析结果

Rini, Brian I; Garrett, May; Poland, Bill; Dutcher, Janice P; Rixe, Olivier; Wilding, George; Stadler, Walter M; Pithavala, Yazdi K; Kim, Sinil; Tarazi, Jamal; Motzer, Robert J

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

酮康唑对健康志愿者体内阿昔替尼药代动力学的影响

Pithavala, Yazdi K; Tong, Warren; Mount, Janessa; Rahavendran, Sadayappan V; Garrett, May; Hee, Brian; Selaru, Paulina; Sarapa, Nenad; Klamerus, Karen J